Document Detail


Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
MedLine Citation:
PMID:  8106694     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The purpose of this study was to examine the incidence and clinical implications of thrombocytopenia that occurs in hospital after administration of thrombolytic therapy for acute myocardial infarction. BACKGROUND: The use of thrombolytic therapy in patients with acute myocardial infarction has improved mortaltiy rates, but hemorrhage remains a major complication. Because thrombocytopenia may be associated with hemorrhage after thrombolytic therapy, we examined the incidence and clinical implications of thrombocytopenia after administration of thrombolytic therapy for acute myocardial infarction. METHODS: The patient population comprised 1,001 patients enrolled in Phases 2, 3 and 5 of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial and the urokinase trial. Patients received recombinant tissue-type plasminogen activator, urokinase or combination therapy in various dosing schemes. All patients received heparin, aspirin and a calcium-channel blocking agent. Thrombocytopenia occurring anytime after thrombolytic therapy was defined as a nadir platelet count either < 100,000/microliters or < 1/2 baseline. Blood loss was quantified by a bleeding index. Multiple logistic regression was used to evaluate the independent contribution of thrombocytopenia in a model predicting in-hospital mortality. RESULTS: Thrombocytopenia occurred in 16.4% of patients, with no difference among the thrombolytic regimens. Patients with thrombocytopenia had a lower median acute ejection fraction and a higher likelihood of three-vessel coronary artery disease than patients without thrombocytopenia. Patients with thrombocytopenia had more hemorrhage, a higher in-hospital mortality rate and a more complicated hospital course than patients without thrombocytopenia, even after consideration of other important variables, including age, acute ejection fraction, number of diseased vessels, bypass surgery and use of intraaortic balloon counterpulsation. CONCLUSIONS: Thrombocytopenia after thrombolytic therapy is a common event and is associated with excess hemorrhage and mortality. Platelet counts should be monitored daily after administration of thrombolytic therapy because the appearance of thrombocytopenia identifies a subset of patients at increased risk for hemorrhage and death.
Authors:
R A Harrington; D C Sane; R M Califf; K N Sigmon; C W Abbottsmith; R J Candela; K L Lee; E J Topol
Related Documents :
2481164 - Do results from major clinical trials indicate a change in management in the acute phas...
10856384 - Degree of residual stenosis in the culprit coronary artery after thrombolytic administr...
8439824 - Prevention of ventricular remodelling post myocardial infarction: timing and duration o...
18806174 - Optimization of perfusion imaging for acute cerebral ischemia: review of recent clinica...
23224924 - Improvement of ventricular function in systolic heart failure patients with oral l-citr...
9838764 - In vitro flow visualization on the right ventricular outflow reconstruction utilizing e...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  23     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1994 Mar 
Date Detail:
Created Date:  1994-03-24     Completed Date:  1994-03-24     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  891-8     Citation Subset:  AIM; IM    
Affiliation:
Division of Cardiology, Duke University Medical Center, Durham, NC.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Female
Hemorrhage / etiology
Hospital Mortality
Humans
Male
Middle Aged
Myocardial Infarction / blood,  drug therapy*,  mortality
Platelet Count
Thrombocytopenia / etiology*
Thrombolytic Therapy / adverse effects*
Grant Support
ID/Acronym/Agency:
HL-17670/HL/NHLBI NIH HHS; HL-36587/HL/NHLBI NIH HHS; HL-45702/HL/NHLBI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical significance of PQ segment depression in acute Q wave anterior wall myocardial infarction.
Next Document:  Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those w...